RU2003137565A - Производные n-формилгидроксиламина в качестве ингибиторов пептидилдеформил азы (pdf) - Google Patents
Производные n-формилгидроксиламина в качестве ингибиторов пептидилдеформил азы (pdf) Download PDFInfo
- Publication number
- RU2003137565A RU2003137565A RU2003137565/04A RU2003137565A RU2003137565A RU 2003137565 A RU2003137565 A RU 2003137565A RU 2003137565/04 A RU2003137565/04 A RU 2003137565/04A RU 2003137565 A RU2003137565 A RU 2003137565A RU 2003137565 A RU2003137565 A RU 2003137565A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compound
- prodrug
- salt
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (12)
1. Соединение формулы (I)
где X означает -СН2-, -S-, -СН(ОН)-, -CH(OR)-, -CH(SH)-, -CH(SR)-, -CF2-, -C=N(OR)- или -CH(F)-, где R означает алкил,
R1 означает арил или гетероарил,
каждый R2, R3, R4 и R5 независимо означает водород или алкил, или (R2 или R3) и (R4 или R5) вместе образуют С4-С7циклоалкил, а
n равно 0-3, при условии, если n равно О, Х означает –СН2-,
или его соль или пролекарство.
2. Соединение по п.1, где Х означает –СН2-, R1 означает гетероарил, R2, R3 и R4 означают водород, R5 означает н-бутил, а n равно 1, или его соль или пролекарство.
3. Соединение по п.1 или 2, где гетероарил означает остаток формулы (II)
где каждый R6, R7, R8 и R9 независимо означает водород, алкил, замещенный алкил, гидрокси, алкокси, ацил, ацилокси, SCN, галоген, циано, нитро, тиоалкокси, фенил, гетероалкиларил, алкилсульфонил или формил, или его соль или пролекарство.
4. Соединение по п.1 или 2, где гетероарил означает остаток формулы (III)
где каждый R6, R7, R8 и R9 независимо означает водород, алкил, замещенный алкил, фенил, галоген, гидрокси или алкокси.
5. Соединение по п.3, где R1 означает гетероарил формулы (II.1)
где R6, R8 и R9 означают водород, a R7 означает этил или метокси, или его соль или пролекарство.
6. Соединение по п.4, где R1 означает гетероарил формулы (III.1)
где R6, R7 и R9 означают водород, a R8 означает фтор или трифторметил, или его соль или пролекарство.
7. Способ получения соединения формулы (I) по п.1, включающий взаимодействие соединения формулы (V)
где R2, R3, R4 и R5 имеют значения, указанные в п.1, a Y означает гидроксизащитную группу или ее функциональное производное, с соединением формулы (VI)
где R1, Х и n имеют значения, указанные в п.1, а X’ означает NH или О, и при необходимости превращение полученных в свободной форме соединений в солевую форму или наоборот.
8. Фармацетическая композиция, включающая соединение формулы I по п.1 или его фармацевтически приемлемую соль или пролекарство в смеси с фармацевтически приемлемым разбавителем или носителем.
9. Соединение формулы I по п.1 или его фармацевтически приемлемая соль или пролекарство для применения в качестве лекарственного средства.
10. Способ лечения и/или профилактики инфекционного нарушения у субъекта, включающий введение субъекту эффективного количества соединения формулы I по п.1, его фармацевтически приемлемой соли или пролекарства.
11. Способ предотвращения бактериальной контаминации клеточной культуральной среды, включающий введение в указанную клеточную культуральную среду подавляющее бактерии количество соединения формулы I по п.1 или его фармацевтически приемлемой соли.
12. Клеточная культуральная среда, включающая подавляющее бактерии количество соединения формулы I по п.1 или его фармацевтически приемлемой соли.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29841901P | 2001-06-15 | 2001-06-15 | |
| US60/298,419 | 2001-06-15 | ||
| US60/298419 | 2001-06-15 | ||
| US36031302P | 2002-02-27 | 2002-02-27 | |
| US60/360,313 | 2002-02-27 | ||
| US60/360313 | 2002-02-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003137565A true RU2003137565A (ru) | 2005-05-27 |
| RU2325386C2 RU2325386C2 (ru) | 2008-05-27 |
Family
ID=26970649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003137565/04A RU2325386C2 (ru) | 2001-06-15 | 2002-06-14 | Производные n-формилгидроксиламина в качестве ингибиторов пептидилдеформилазы (pdf) |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7148242B2 (ru) |
| EP (1) | EP1401828B1 (ru) |
| JP (1) | JP4361365B2 (ru) |
| KR (2) | KR20060014083A (ru) |
| CN (1) | CN1511152A (ru) |
| AR (1) | AR036053A1 (ru) |
| AT (1) | ATE323081T1 (ru) |
| AU (1) | AU2002321062B2 (ru) |
| BR (1) | BR0210377A (ru) |
| CA (1) | CA2448526A1 (ru) |
| CO (1) | CO5640131A2 (ru) |
| CY (1) | CY1105085T1 (ru) |
| CZ (1) | CZ20033388A3 (ru) |
| DE (1) | DE60210612T2 (ru) |
| DK (1) | DK1401828T3 (ru) |
| ES (1) | ES2262824T3 (ru) |
| HK (1) | HK1064370A1 (ru) |
| HU (1) | HUP0400208A3 (ru) |
| IL (1) | IL158770A0 (ru) |
| MX (1) | MXPA03011628A (ru) |
| MY (1) | MY138619A (ru) |
| NO (1) | NO327420B1 (ru) |
| NZ (1) | NZ529489A (ru) |
| PE (1) | PE20030100A1 (ru) |
| PL (1) | PL364476A1 (ru) |
| PT (1) | PT1401828E (ru) |
| RU (1) | RU2325386C2 (ru) |
| SI (1) | SI1401828T1 (ru) |
| SK (1) | SK15242003A3 (ru) |
| WO (1) | WO2002102790A1 (ru) |
| ZA (1) | ZA200308379B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60219630T2 (de) * | 2001-06-15 | 2007-12-27 | Vicuron Pharmaceuticals, Inc., Fremont | Bicyclische pyrrolidinverbindungen |
| GB0208579D0 (en) * | 2002-04-13 | 2002-05-22 | British Biotech Pharm | Antibacterial agents |
| WO2004026824A1 (en) | 2002-09-19 | 2004-04-01 | Novartis Ag | Process for preparing intermediates |
| AU2004216178B2 (en) * | 2003-02-21 | 2008-07-03 | Novartis Ag | Chemical process for the preparation of intermediates to obtain N-formyl hydroxylamine compounds |
| TW200427458A (en) * | 2003-04-02 | 2004-12-16 | Novartis Ag | Crystalline N-formyl hydroxylamine compounds |
| US20070060753A1 (en) * | 2003-06-26 | 2007-03-15 | Joel Slade | Process for preparing intermediates useful to prepare certain antibacterial n-formyl hydroxylamines |
| KR100527624B1 (ko) * | 2003-08-21 | 2005-11-22 | 한기종 | 질소에 포밀기를 갖는 아민유도체의 새로운 제조방법 |
| WO2006002896A1 (en) * | 2004-06-30 | 2006-01-12 | Novartis Ag | Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors |
| US20080161249A1 (en) * | 2004-11-17 | 2008-07-03 | Smithkline Beecham Corporation | Use of Novel Antibacterial Compounds |
| GT200600196A (es) | 2005-05-23 | 2007-01-15 | Compuestos n-formil de hidroxilamina | |
| MX2007015421A (es) | 2005-06-07 | 2008-02-21 | Novartis Ag | Inhibidores de desformilasa peptidica (pdf) 4. |
| DE102005026231A1 (de) * | 2005-06-07 | 2006-12-14 | Origenis Ag | Peptid-Deformylase (PDF) Inhibitoren 3 |
| SG133452A1 (en) * | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| MX2008011128A (es) * | 2006-03-03 | 2008-09-08 | Novartis Ag | Compuestos de n-formil-hidroxilamina. |
| CN101328155B (zh) * | 2007-06-20 | 2010-11-03 | 上海医药工业研究院 | 噁唑烷衍生物及其制备方法和应用 |
| CN101434570B (zh) * | 2007-11-16 | 2011-02-02 | 上海医药工业研究院 | 吡咯烷衍生物及其制备方法和应用 |
| CN101584694B (zh) * | 2009-06-15 | 2011-01-12 | 华东师范大学 | 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法 |
| EP2473502A1 (en) * | 2009-09-04 | 2012-07-11 | Novartis AG | Heteroaryl compounds as kinase inhibitors |
| NZ627520A (en) | 2010-03-10 | 2015-10-30 | Astrazeneca Ab | 4-phenyl pyridine analogues as protein kinase inhibitors |
| JP5825086B2 (ja) | 2011-12-19 | 2015-12-02 | 住友化学株式会社 | α−置換−β−アミノ酸エステル誘導体不斉加水分解酵素 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| EP3280795B1 (en) | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| US10738028B2 (en) * | 2016-05-11 | 2020-08-11 | Rudong Ruien Pharmaceutical Technology Co. Ltd | Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052511A (en) * | 1976-02-13 | 1977-10-04 | E. R. Squibb & Sons, Inc. | Carboxyacylproline derivatives |
| US4311705A (en) * | 1980-10-06 | 1982-01-19 | E. R. Squibb & Sons, Inc. | Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines |
| US4321383A (en) * | 1980-11-24 | 1982-03-23 | E. R. Squibb & Sons, Inc. | Heterobicyclo intermediates |
| US4303662A (en) * | 1980-11-24 | 1981-12-01 | E. R. Squibb & Sons, Inc. | Carboxyacyl, mercapto and acylmercapto derivatives of heterobicyclo compounds |
| JPS6188884A (ja) * | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | エンケフアリナ−ゼｂ阻害物質およびその製法 |
| US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| DK77487A (da) | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
| FR2609289B1 (fr) | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
| US5128346A (en) * | 1987-09-21 | 1992-07-07 | Abbott Laboratories | Derivatives of D-glutamic acid and D-aspartic acid |
| EP0334244A3 (en) | 1988-03-25 | 1991-05-29 | The Procter & Gamble Company | Bradykinin antagonist peptides |
| GB8827308D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| GB8919251D0 (en) | 1989-08-24 | 1989-10-04 | British Bio Technology | Compounds |
| GB8921326D0 (en) | 1989-09-21 | 1989-11-08 | Beecham Group Plc | Novel treatment |
| US5268384A (en) * | 1990-11-21 | 1993-12-07 | Galardy Richard E | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
| DK0489579T3 (da) | 1990-12-03 | 1995-06-12 | Celltech Therapeutics Ltd | Peptidylderivater |
| CA2058797A1 (en) | 1991-02-01 | 1992-08-02 | Michael John Broadhurst | Amino acid derivatives |
| GB9102635D0 (en) | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
| IT1245712B (it) * | 1991-04-09 | 1994-10-14 | Boehringer Mannheim Italia | Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree |
| WO1992022523A2 (en) | 1991-06-14 | 1992-12-23 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
| US5256657A (en) * | 1991-08-19 | 1993-10-26 | Sterling Winthrop, Inc. | Succinamide derivative matrix-metalloprotease inhibitors |
| JPH05125029A (ja) | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
| WO1993009097A1 (en) | 1991-11-08 | 1993-05-13 | Sankyo Company, Limited | Collagenase inhibitor |
| WO1993020047A1 (en) | 1992-04-07 | 1993-10-14 | British Bio-Technology Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
| GB9211707D0 (en) | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
| GB9211706D0 (en) | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
| US5318964A (en) * | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
| GB9215665D0 (en) | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
| US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| CA2136108A1 (en) | 1993-03-18 | 1994-09-29 | Makoto Sakamoto | Carbostyril derivatives as matrix metalloproteinases inhibitors |
| US5714491A (en) | 1993-04-27 | 1998-02-03 | Celltech Therapeutics Limited | Peptidyl derivatives as metalloproteinase inhibitors |
| GB9308695D0 (en) | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
| GB9501737D0 (en) | 1994-04-25 | 1995-03-22 | Hoffmann La Roche | Hydroxamic acid derivatives |
| GB9411598D0 (en) | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
| GB9502858D0 (en) | 1995-02-14 | 1995-04-05 | British Biotech Pharm | Novel use of matrix metalloproteinase inhibitors |
| GB9504084D0 (en) | 1995-03-01 | 1995-04-19 | British Biotech Pharm | Synthesis of carboxylic and hydroxamic acid derivatives |
| FR2733750B1 (fr) | 1995-05-03 | 1997-06-13 | Synthelabo | Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique |
| DK0939632T3 (da) | 1996-02-23 | 2006-01-30 | Lilly Co Eli | Non-peptidyl vasopressin V1a antagonister |
| TW448172B (en) | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| GB9613547D0 (en) | 1996-06-27 | 1996-08-28 | Pharmacia Spa | Matrix metalloproteinase inhibitors |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| EP0925289A1 (en) | 1997-07-10 | 1999-06-30 | PHARMACIA & UPJOHN S.p.A. | Matrix metalloproteinase inhibitors |
| ES2221359T3 (es) | 1998-02-07 | 2004-12-16 | Vernalis (Oxford) Ltd | Agentes antibacterianos. |
-
2002
- 2002-06-13 AR ARP020102229A patent/AR036053A1/es not_active Application Discontinuation
- 2002-06-14 NZ NZ529489A patent/NZ529489A/en unknown
- 2002-06-14 SK SK1524-2003A patent/SK15242003A3/sk not_active Application Discontinuation
- 2002-06-14 CN CNA028105966A patent/CN1511152A/zh active Pending
- 2002-06-14 PE PE2002000516A patent/PE20030100A1/es not_active Application Discontinuation
- 2002-06-14 AT AT02754681T patent/ATE323081T1/de not_active IP Right Cessation
- 2002-06-14 PL PL02364476A patent/PL364476A1/xx not_active Application Discontinuation
- 2002-06-14 BR BR0210377-0A patent/BR0210377A/pt not_active IP Right Cessation
- 2002-06-14 KR KR1020067002113A patent/KR20060014083A/ko not_active Application Discontinuation
- 2002-06-14 WO PCT/EP2002/006604 patent/WO2002102790A1/en active IP Right Grant
- 2002-06-14 EP EP02754681A patent/EP1401828B1/en not_active Expired - Lifetime
- 2002-06-14 JP JP2003506263A patent/JP4361365B2/ja not_active Expired - Fee Related
- 2002-06-14 MY MYPI20022243A patent/MY138619A/en unknown
- 2002-06-14 KR KR1020037016435A patent/KR100589544B1/ko not_active IP Right Cessation
- 2002-06-14 DE DE60210612T patent/DE60210612T2/de not_active Expired - Lifetime
- 2002-06-14 CA CA002448526A patent/CA2448526A1/en not_active Abandoned
- 2002-06-14 ES ES02754681T patent/ES2262824T3/es not_active Expired - Lifetime
- 2002-06-14 AU AU2002321062A patent/AU2002321062B2/en not_active Ceased
- 2002-06-14 MX MXPA03011628A patent/MXPA03011628A/es active IP Right Grant
- 2002-06-14 PT PT02754681T patent/PT1401828E/pt unknown
- 2002-06-14 HU HU0400208A patent/HUP0400208A3/hu unknown
- 2002-06-14 US US10/171,706 patent/US7148242B2/en not_active Expired - Fee Related
- 2002-06-14 CZ CZ20033388A patent/CZ20033388A3/cs unknown
- 2002-06-14 SI SI200230358T patent/SI1401828T1/sl unknown
- 2002-06-14 IL IL15877002A patent/IL158770A0/xx unknown
- 2002-06-14 DK DK02754681T patent/DK1401828T3/da active
- 2002-06-14 RU RU2003137565/04A patent/RU2325386C2/ru not_active IP Right Cessation
-
2003
- 2003-10-28 ZA ZA200308379A patent/ZA200308379B/en unknown
- 2003-12-03 CO CO03106413A patent/CO5640131A2/es not_active Application Discontinuation
- 2003-12-12 NO NO20035571A patent/NO327420B1/no not_active IP Right Cessation
-
2004
- 2004-09-14 HK HK04107013A patent/HK1064370A1/xx not_active IP Right Cessation
-
2006
- 2006-07-12 CY CY20061100965T patent/CY1105085T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003137565A (ru) | Производные n-формилгидроксиламина в качестве ингибиторов пептидилдеформил азы (pdf) | |
| RU2505532C2 (ru) | Соединение | |
| RU2481346C2 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| RU2007123235A (ru) | Противоопухолевые соединения | |
| RU2309951C2 (ru) | Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение | |
| RU2397976C2 (ru) | Производные бензамидов и гетероаренов | |
| RU2200730C2 (ru) | Пара-терфенильные соединения, способ их получения (варианты) и фармацевтическая композиция (варианты) | |
| RU2004130488A (ru) | Пиримидиновые производные | |
| RU2006112593A (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk | |
| RS54607B1 (en) | 5-SUBSTITUATED HINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | |
| RU2003122196A (ru) | Органические соединения | |
| RU2000127751A (ru) | Противоопухолевое средство | |
| JP2005538072A5 (ru) | ||
| RU2006125630A (ru) | Дифенилаэетидиноновые производные, обладающие активностью, ингибирующей всасывание холестерина | |
| RU2007147340A (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| PE20050073A1 (es) | Nuevas quinazolinonas espirocondensadas inhibidoras de la fosfodiesterasa | |
| CA2455768A1 (en) | Antitumoral analogs of et-736 | |
| RU2004114240A (ru) | Органические соединения | |
| RU2004118247A (ru) | Бензимидазол-или индоламиноацетонитрильные производные для борьбы с паразитами | |
| EP1465488A4 (en) | ARYLAMINES AS INHIBITORS OF THE BINDING OF CHEMOKINE A US28 | |
| RU97115107A (ru) | Бициклические производные изотиомочевины, применяемые в терапии | |
| RU2004120790A (ru) | Аминоацетонитрильные производные и их применение для борьбы с паразитами | |
| RU99115165A (ru) | Способ получения производных тиазола | |
| RU2005101203A (ru) | N-сульфониламиноацетонитрилы, обладающие пестицидными свойствами | |
| RU2003122785A (ru) | 9a-n-[n`-(фенилсульфонил)карбамоил)-производные 9-дезоксо-9-дигидро-9a-аза-9a-гомоэритромицина a и 5-o-дезозаминил-9-дезоксо-9-дигидро-9a-аза-9a-гомоэритронолида a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100615 |